New Delhi, April 4 (NationPress) In response to the escalating demand for weight-loss and diabetes medications, particularly GLP-1 receptor agonists, India's drug regulatory authorities are enhancing their monitoring efforts. This action is prompted by the expected introduction of affordable generic alternatives into the domestic market.

The Indian Pharmacopoeia Commission (IPC), operating under the Ministry of Health, has been assigned the critical role of systematically gathering and assessing reports of adverse events associated with these medications.

This initiative is designed to fortify post-marketing surveillance and ensure that any safety issues are swiftly recognized and resolved.

Officials have stated that this measure is part of a comprehensive regulatory strategy to adapt to the rapid adoption of these therapies, particularly as they become more accessible to the public.

With the patent expiration of semaglutide, a vital component of popular weight-loss solutions, a surge of low-cost generic options is anticipated, broadening access but also increasing the potential for misuse.

The enhanced scrutiny follows recent enforcement actions by the Drug Controller General of India (DCGI), which has intensified inspections to combat unauthorized sales and promotions of GLP-1 drugs.

In the past few weeks, inspections have been conducted at 49 locations nationwide, including online pharmacy warehouses, wholesalers, retailers, and weight-loss clinics.

These audits concentrated on detecting violations like selling without prescriptions, inappropriate prescribing methods, and deceptive marketing practices.

Notices have been issued to those found in violation, with the government warning that ongoing non-compliance could result in license revocation, financial penalties, and legal repercussions.

The Centre has also clarified that only qualified specialists, including endocrinologists, internal medicine practitioners, and cardiologists, are permitted to prescribe these medications.

Previously, on March 10, the government instructed manufacturers to cease misleading advertisements and any promotional activities that could promote unsupervised usage.

GLP-1 receptor agonists, commonly used for treating type 2 diabetes and increasingly utilized for weight management, operate by stimulating insulin secretion and curbing appetite through the delay of gastric emptying.

Nonetheless, health authorities have warned about potential side effects, which can range from nausea and vomiting to serious complications such as pancreatitis, kidney damage, and bowel obstruction.